Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccination Followed by TACE for Advanced Hepatocellular Carcinoma
NCT07726329Phase 2Active, not recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jul 2019
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor mRNA-transfected dendritic cell vaccine (Oslo University Hospital) in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Jul 2019; status: active, not recruiting.
02
Drugs
autologous tumor mRNA-transfected dendritic cell vaccine (Oslo University Hospital)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07726329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726329.